UBS analyst John Sourbeer upgrades Medpace Hldgs (NASDAQ:MEDP) from Neutral to Buy and raises the price target from $282 to $452.
UBS Upgrades Medpace Hldgs to Buy, Raises Price Target to $452
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.